168 related articles for article (PubMed ID: 19389846)
1. Possible effects of the new Medicare reimbursement policy on African Americans with ESRD.
Ishani A; Guo H; Arneson TJ; Gilbertson DT; Mau LW; Li S; Dunning S; Collins AJ
J Am Soc Nephrol; 2009 Jul; 20(7):1607-13. PubMed ID: 19389846
[No Abstract] [Full Text] [Related]
2. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
[TBL] [Abstract][Full Text] [Related]
3. Bundled payment for ESRD--including ESAs in Medicare's dialysis package.
Iglehart JK
N Engl J Med; 2011 Feb; 364(7):593-5. PubMed ID: 21323538
[No Abstract] [Full Text] [Related]
4. Toward Antiracist Reimbursement Policy in End-Stage Kidney Disease: From Equality to Equity.
Taylor K; Crews DC
J Am Soc Nephrol; 2021 Oct; 32(10):2422-2424. PubMed ID: 34253586
[No Abstract] [Full Text] [Related]
5. Is it time for Medicare to provide reimbursement for daily hemodialysis?
Newmann JM
Nephrol News Issues; 2001 Apr; 15(5):57-9. PubMed ID: 12108965
[No Abstract] [Full Text] [Related]
6. Challenges and directions for Medicare ESRD payment policy.
Ray NF; Ross M
Semin Nephrol; 2000 Nov; 20(6):565-76. PubMed ID: 11111858
[TBL] [Abstract][Full Text] [Related]
7. The Medicare end-stage renal disease program. A report from the Institute of Medicine.
Levinsky NG; Rettig RA
N Engl J Med; 1991 Apr; 324(16):1143-8. PubMed ID: 2008193
[No Abstract] [Full Text] [Related]
8. Medicare Enrollment Among Patients With End-Stage Kidney Disease Receiving Dialysis in Outpatient Facilities Between 2005 and 2016.
Hoffman A; Sloan CE; Maciejewski ML; Wang V
JAMA; 2020 Apr; 323(13):1314-1316. PubMed ID: 32259222
[TBL] [Abstract][Full Text] [Related]
9. Racial/ethnic and gender disparities in the use of erythropoiesis-stimulating agents and blood transfusions: cancer management under Medicare's reimbursement policy.
Li M; Schulz R; Chisholm-Burns M; Wang J; Lu ZK
J Manag Care Spec Pharm; 2020 Nov; 26(11):1477-1486. PubMed ID: 33119441
[No Abstract] [Full Text] [Related]
10. Anemia: dialysis patients experiences.
Schatell D; Witten B
Nephrol News Issues; 2004 Nov; 18(12):49-54. PubMed ID: 15595502
[No Abstract] [Full Text] [Related]
11. What can we expect down the road?
Sullivan J
Nephrol News Issues; 2011 Apr; 25(4):28-9. PubMed ID: 21542511
[No Abstract] [Full Text] [Related]
12. Out-of-network payments for ESRD care: the National Renal Alliance case.
Riley JB; Soldato D
Nephrol News Issues; 2008 Jul; 22(8):56, 58. PubMed ID: 18711884
[No Abstract] [Full Text] [Related]
13. Medicare and erythropoietin.
Steinbrook R
N Engl J Med; 2007 Jan; 356(1):4-6. PubMed ID: 17202449
[No Abstract] [Full Text] [Related]
14. Futuristic plans for ESRD--a new bundled payment system.
Michael M
Nephrol News Issues; 2005 Sep; 19(10):52, 54. PubMed ID: 16187649
[No Abstract] [Full Text] [Related]
15. Regional Variations in the Interpretation of the End-Stage Renal Disease Thirty-Month Coordination Period: Potential Implications for Patient Care.
Harford R; Clark MJ; Yan G; Flaque J; Colon J; Torre F; Rodriguez Y; Norris KC
J Health Care Poor Underserved; 2017; 28(4):1245-1253. PubMed ID: 29176092
[TBL] [Abstract][Full Text] [Related]
16. Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management?
Turenne MN; Cope EL; Porenta S; Mukhopadhyay P; Fuller DS; Pearson JM; Dahlerus C; Lantz B; Tentori F; Robinson BM
J Am Soc Nephrol; 2015 Mar; 26(3):754-64. PubMed ID: 25300289
[TBL] [Abstract][Full Text] [Related]
17. X. The economic cost of ESRD and Medicare spending for alternative modalities of treatment.
Am J Kidney Dis; 1999 Aug; 34(2 Suppl 1):S124-39. PubMed ID: 10431009
[No Abstract] [Full Text] [Related]
18. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
Wish JB
Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin & ESRD payments: a promising policy outcome?
Roe W
Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
[No Abstract] [Full Text] [Related]
20. Survival Disparity of African American Versus Non-African American Patients With ESRD Due to SLE.
Nee R; Martinez-Osorio J; Yuan CM; Little DJ; Watson MA; Agodoa L; Abbott KC
Am J Kidney Dis; 2015 Oct; 66(4):630-7. PubMed ID: 26002293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
